Ministry of Science & Technology press release · 17 March 2026 · pibtracker filter

“TDB-DST supports Acrannolife Genomics Private Limited, Chennai for Indigenous Manufacturing of Advanced IVD Diagnostic Kits”

PRID2241259 MinistryMinistry of Science & Technology Released17 March 2026 Reading9 min

Posted On: 17 MAR 2026 4:45PM by PIB Delhi The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial assistance to Acrannolife Genomics Private Limited, Chennai for the project titled “Indigenizing IVD Innovation: Establishing a State-of-the-Art Manufacturing Facility to Drive Scalable and Sustainable Growth of Trunome GrafAssure IVD Kits and TBFYND IVD Kits.” The project focuses on establishing an advanced manufacturing facility to support the large-scale production and deployment of indigenous in-vitro diagnostic (IVD) solutions developed by the company. Acrannolife Genomics Private Limited is engaged in developing innovative non-invasive diagnostic technologies based on cell-free DNA and LAMP technology platforms, addressing critical healthcare needs such as infectious diseases and transplant diagnostics. Through this project, the company will establish a state-of-the-art manufacturing facility at the TANSIDCO Industrial Estate to scale up production of two key diagnostic products—Trunome GrafAssure and TBFYND. The company’s flagship product, Trunome GrafAssure, is a laboratory-developed blood test designed for the early detection of post-transplant organ rejection and infection in patients who have undergone solid-organ transplants. The test utilizes advanced cell-free DNA analysis to provide high diagnostic sensitivity and specificity, enabling clinicians to detect signs of rejection or infection weeks before clinical symptoms appear, thereby supporting timely medical intervention and improved patient outcomes. The second product, TBFYND, is designed to address the urgent need for rapid and accurate detection of tuberculosis, one of the most significant public health challenges in India. Both diagnostic kits are fully developed in-house with secured intellectual property and will be processed through the company’s proprietary software platform, ensuring reliable and scalable diagnostic workflows. With support from TDB, the project will enable the creation of a dedicated platform facility for manufacturing these IVD kits at scale, strengthening India’s domestic capabilities in molecular diagnostics and reducing dependence on imported diagnostic technologies. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated that the Board remains committed to supporting indigenous biotechnological innovations that translate cutting-edge research into affordable and accessible healthcare solutions. He noted that the establishment of advanced manufacturing capabilities for diagnostic technologies will play a vital role in strengthening India’s healthcare ecosystem and promoting self-reliance in critical medical technologies. Promoters of Acrannolife Genomics Private Limited expressed appreciation for the support extended by TDB and highlighted that the assistance will enable the company to scale up production, accelerate deployment of its diagnostic kits, and expand access to innovative genomic diagnostics for patients and healthcare providers. ******** NKR/FT (Release ID: 2241259) Visitor Counter : 518 Read this release in: हिन्दी , Urdu Ministry of Science & Technology “TDB-DST supports Acrannolife Genomics Private Limited, Chennai for Indigenous Manufacturing of Advanced IVD Diagnostic Kits” Posted On: 17 MAR 2026 4:45PM by PIB Delhi The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial assistance to Acrannolife Genomics Private Limited, Chennai for the project titled “Indigenizing IVD Innovation: Establishing a State-of-the-Art Manufacturing Facility to Drive Scalable and Sustainable Growth of Trunome GrafAssure IVD Kits and TBFYND IVD Kits.” The project focuses on establishing an advanced manufacturing facility to support the large-scale production and deployment of indigenous in-vitro diagnostic (IVD) solutions developed by the company. Acrannolife Genomics Private Limited is engaged in developing innovative non-invasive diagnostic technologies based on cell-free DNA and LAMP technology platforms, addressing critical healthcare needs such as infectious diseases and transplant diagnostics. Through this project, the company will establish a state-of-the-art manufacturing facility at the TANSIDCO Industrial Estate to scale up production of two key diagnostic products—Trunome GrafAssure and TBFYND. The company’s flagship product, Trunome GrafAssure, is a laboratory-developed blood test designed for the early detection of post-transplant organ rejection and infection in patients who have undergone solid-organ transplants. The test utilizes advanced cell-free DNA analysis to provide high diagnostic sensitivity and specificity, enabling clinicians to detect signs of rejection or infection weeks before clinical symptoms appear, thereby supporting timely medical intervention and improved patient outcomes. The second product, TBFYND, is designed to address the urgent need for rapid and accurate detection of tuberculosis, one of the most significant public health challenges in India. Both diagnostic kits are fully developed in-house with secured intellectual property and will be processed through the company’s proprietary software platform, ensuring reliable and scalable diagnostic workflows. With support from TDB, the project will enable the creation of a dedicated platform facility for manufacturing these IVD kits at scale, strengthening India’s domestic capabilities in molecular diagnostics and reducing dependence on imported diagnostic technologies. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated that the Board remains committed to supporting indigenous biotechnological innovations that translate cutting-edge research into affordable and accessible healthcare solutions. He noted that the establishment of advanced manufacturing capabilities for diagnostic technologies will play a vital role in strengthening India’s healthcare ecosystem and promoting self-reliance in critical medical technologies. Promoters of Acrannolife Genomics Private Limited expressed appreciation for the support extended by TDB and highlighted that the assistance will enable the company to scale up production, accelerate deployment of its diagnostic kits, and expand access to innovative genomic diagnostics for patients and healthcare providers. ******** NKR/FT (Release ID: 2241259) The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial assistance to Acrannolife Genomics Private Limited, Chennai for the project titled “Indigenizing IVD Innovation: Establishing a State-of-the-Art Manufacturing Facility to Drive Scalable and Sustainable Growth of Trunome GrafAssure IVD Kits and TBFYND IVD Kits.” The project focuses on establishing an advanced manufacturing facility to support the large-scale production and deployment of indigenous in-vitro diagnostic (IVD) solutions developed by the company. Acrannolife Genomics Private Limited is engaged in developing innovative non-invasive diagnostic technologies based on cell-free DNA and LAMP technology platforms, addressing critical healthcare needs such as infectious diseases and transplant diagnostics. Through this project, the company will establish a state-of-the-art manufacturing facility at the TANSIDCO Industrial Estate to scale up production of two key diagnostic products—Trunome GrafAssure and TBFYND. The company’s flagship product, Trunome GrafAssure, is a laboratory-developed blood test designed for the early detection of post-transplant organ rejection and infection in patients who have undergone solid-organ transplants. The test utilizes advanced cell-free DNA analysis to provide high diagnostic sensitivity and specificity, enabling clinicians to detect signs of rejection or infection weeks before clinical symptoms appear, thereby supporting timely medical intervention and improved patient outcomes. The second product, TBFYND, is designed to address the urgent need for rapid and accurate detection of tuberculosis, one of the most significant public health challenges in India. Both diagnostic kits are fully developed in-house with secured intellectual property and will be processed through the company’s proprietary software platform, ensuring reliable and scalable diagnostic workflows. With support from TDB, the project will enable the creation of a dedicated platform facility for manufacturing these IVD kits at scale, strengthening India’s domestic capabilities in molecular diagnostics and reducing dependence on imported diagnostic technologies. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated that the Board remains committed to supporting indigenous biotechnological innovations that translate cutting-edge research into affordable and accessible healthcare solutions. He noted that the establishment of advanced manufacturing capabilities for diagnostic technologies will play a vital role in strengthening India’s healthcare ecosystem and promoting self-reliance in critical medical technologies. Promoters of Acrannolife Genomics Private Limited expressed appreciation for the support extended by TDB and highlighted that the assistance will enable the company to scale up production, accelerate deployment of its diagnostic kits, and expand access to innovative genomic diagnostics for patients and healthcare providers. <img alt="" src="https://static.pib.gov.in/WriteReadData/userfiles/image/picfortheDBTPRSHUH.jpg" style="height:300px; width:500px" />  ******** NKR/FT " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //

Original PIB release
pib.gov.in · PRID 2241259

Open on PIB ↗

“TDB-DST supports Acrannolife Genomics Private Limited, Chennai for Indigenous Manufacturing of Advanced IVD Diagnostic Kits”

More from this day